AI-assisted analysis based on the official CRS summary. Source version: Sep 14, 2026. Analysis updated: Sep 15, 2026.
01 — The Text
What.
- The bill eliminates the requirement for biosimilar applicants to submit a clinical efficacy study as a condition of FDA approval.
- The FDA retains authority to require a clinical efficacy study if it determines one is necessary.
- If the FDA requires a clinical efficacy study, it must provide a written determination of necessity to the applicant within a specified period.
- The bill eliminates the requirement that a biosimilar application be reviewed by the same FDA division responsible for reviewing the reference product application.
- Current FDA discretion to waive studies it deems unnecessary remains unchanged under law.
02 — The Stakes
So what?
- The change applies to proposed biological products including drugs and vaccines; documented effects on approval timelines or costs are not established in the official summary.
- The FDA's October 2025 draft guidance suggesting clinical efficacy studies may be unnecessary for some therapeutic protein products is cited as context but does not constitute documented effect of this bill.
- The impact on drug development, patient access, or product safety is not established in the official summary.
- No winners, losers, or quantified effects are documented.
03 — The Path
Now what?
- Senate committee reported the bill with an amendment on July 27, 2026, and placed it on the Senate Legislative Calendar.
- The bill was introduced in the Senate on April 10, 2025, and referred to the Committee on Health, Education, Labor, and Pensions.
- No scheduled vote date is documented.
Legislative History
Actions.
- Jul 27, 2026 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026 — Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Apr 10, 2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Apr 10, 2025 — Introduced in Senate